GM Advisory Group LLC Purchases 1,300 Shares of GSK plc (NYSE:GSK)

GM Advisory Group LLC lifted its position in GSK plc (NYSE:GSK) by 19.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,035 shares of the pharmaceutical company’s stock after acquiring an additional 1,300 shares during the period. GM Advisory Group LLC’s holdings in GSK were worth $272,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC raised its holdings in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC lifted its position in GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC boosted its stake in GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after acquiring an additional 165,556 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in GSK by 9.7% in the third quarter. Stifel Financial Corp now owns 604,973 shares of the pharmaceutical company’s stock worth $24,731,000 after purchasing an additional 53,440 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $39.53 on Thursday. The firm has a market cap of $81.81 billion, a P/E ratio of 24.86, a PEG ratio of 1.12 and a beta of 0.58. The company has a 50 day moving average of $36.42 and a 200 day moving average of $36.98. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 3.98%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is presently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.